We are excited to announce ground-breaking results from SURVEYOR, a clinical trial focused on cognitive changes in individuals with Huntington’s disease (HD). This trial tested the short-term safety and efficacy of dalzanemdor in improving cognitive symptoms, and we can report that it has successfully met its key goals! The positive outcomes mark a significant step forward in enhancing the lives of those affected by HD.

Click below to know more about SAGE therapeutic’s study on Dalzanemdor and the impact of this news on the community…